IJBPAS, September, 2026, 15(9): 4424-4454

ISSN: 2277–4998

International Journal of Biology, Pharmacy and Allied Sciences (IJBPAS)

'A Bridge Between Laboratory and Reader'

www.ijbpas.com

ULTRA-DEFORMABLE VESICLES: A COMPREHENSIVE GUIDE TO TRANSFERSOMES IN BIOMEDICINEFOR ENHANCED DRUG DELIVERY

R. SUNITHA[1*], P SIVADASU[1], S. BHUVANESWAR[2], K. KEERTHI[2], N. SUNITHA[2], J. DEEPIKA S[2], P. PRASANNA KUMARI[2], V. MANI[2] AND SK. PARVEZ[2]

1: Research Scholar, Department of Pharmacy, K L College of Pharmacy, Koneru Lakshmaiah Education Foundation, Vaddeswaram, Andhra Pradesh, India-522302.

2: Assistant Professor, Department of Pharmacy, K L College of Pharmacy, Koneru Lakshmaiah Education Foundation, Vaddeswaram, Andhra Pradesh, India-522302.

3: A. M. Reddy Memorial College of Pharmacy, Petlurivari Palem, Narasaraopet, A.P., India, Pin-522601

***Corresponding Author: Dr. R. Sunitha: E Mail: raminenisunitha@gmail.com**

Received 12th Nov. 2025; Revised 18th Dec. 2025; Accepted 8th April 2026; Available online 1st Sept. 2026

https://doi.org/10.31032/IJBPAS/2026/15.9.10477

ABSTRACT

The skin's barrier function presents a significant obstacle for simple, non-invasive drug delivery methods. Conventional liposomes and niosomes are not well-suited for transdermal delivery because they struggle to penetrate the skin effectively, are prone to instability and drug leakage, and often clump and merge together. Transfersomes, designed specifically to overcome these limitations, offer a promising alternative. Transfersomes, however, are specifically engineered to address these shortcomings. These artificially created vesicles are designed to emulate the behavior of natural cell vesicles or cells undergoing exocytosis. The ultra-deformable lipid membranes of Transfersomes allow them to potentially overcome the challenges of transdermal delivery. This paper provides a comprehensive exploration of Transfersomes, covering their composition, mechanism of action, advantages, disadvantages, preparation, characterization, and diverse applications in pharmaceuticals and biomedicine. Furthermore, the paper discusses successful research in transferosomal delivery and examples of marketed products,

highlighting their potential to revolutionize targeted therapies by improving drug delivery across the skin.

Keywords: transferosomes, TDDS, Film hydration technique, Phospholipids, lipid based formulations

INTRODUCTION:

Transferosome is the trademarked name for a proprietary technology developed by the German company IDEA AG. Essentially, it refers to their unique delivery system, and the term's Latin roots can be interpreted as "body carrying." This name is derived from the Latin word "**transferre,"** meaning "**carrying across,"** combined with the Greek word "**soma,"** meaning "body."

A Transfersome is a type of artificially engineered vesicle that is designed to mimic the properties of a natural cell vesicle or a cell undergoing the process of exocytosis. This design feature makes it an excellent choice for controlled and potentially targeted drug delivery. The membrane of a Transfersome is highly flexible and self-regulating, which contributes to its exceptional deformability.

Transdermal drug delivery systems have gained considerable attention as a convenient and non-invasive alternative to traditional methods such as oral and injectable administrations. This approach offers several advantages, including improved patient compliance, reduced side effects, and the potential for controlled release of medications. However, one significant challenge associated with transdermal drug delivery is the limitation in permeation across the skin's robust barrier, primarily formed by the stratum corneum.

To overcome these barriers and enhance drug permeation, innovative technologies have been developed, one of which is Transfersomes. These are ultra-deformable lipid vesicles that have demonstrated promising potential in improving drug delivery across the skin. Transfersomes are composed of phospholipids, edge activators, and occasionally, additional components such as surfactants or co-solvents. This unique composition allows Transfersomes to adapt to the environmental conditions and deform when subjected to pressure, thus efficiently transporting drugs through the skin's pores and across its barrier.

The utilization of Transfersomes in drug delivery offers several advantages over conventional transdermal drug delivery systems. Firstly, Transfersomes can significantly improve drug permeation across the skin due to their high deformability, allowing efficient drug transport even through small pores in the stratum corneum. Secondly, these ultra-deformable vesicles can encapsulate both hydrophilic and hydrophobic drugs, thus

expanding the range of drugs suitable for transdermal delivery. Thirdly, Transfersomes can protect the encapsulated drug from degradation and enzymatic reactions, ensuring drug stability and enhancing its bioavailability.

Despite their advantages, Transfersomes also have limitations and challenges that need to be considered. The primary concern is the potential for skin irritation and sensitization due to the presence of edge activators, which may limit their applicability in specific patient populations. Additionally, the preparation process for Transfersomes can be complex, requiring precise control over composition and manufacturing conditions. Further research is required to optimize the Transfersomes preparation process, explore novel edge activators and excipients that minimize skin irritation, and evaluate their long-term safety and efficacy.

Potential applications for Transfersomes in the pharmaceutical and biomedical fields are vast and varied. These ultra-deformable vesicles can be employed for the targeted delivery of drugs in various therapeutic areas such as pain management, wound healing, and dermatology. They also show promise in cosmetic and personal care products, where they can enhance the delivery of active ingredients and improve product efficacy.

Traditional liposomal and niosomal systems are not ideal for transdermal delivery due to their limited skin penetration, instability, drug leakage, and tendency to aggregate and fuse. Transfersomes, on the other hand, were designed to overcome these limitations. They provide a carrier system that can deliver both low and high molecular weight drugs through the skin, thanks to their specially optimized, ultra-deformable lipid structures. These structures can penetrate the intact mammalian skin, making them a valuable tool in the field of drug delivery.

Transfersomes are a sophisticated type of vesicular drug delivery system, each designed to encapsulate and transport therapeutic molecules. At their core, each Transfersome features at least a single, internal, water-based (aqueous) compartment. This compartment is where the active pharmaceutical ingredient (API) or other cargo is typically housed. Crucially, this aqueous core is completely enveloped by a lipid bilayer, a structure akin to that of a cell membrane. This bilayer provides the necessary barrier to protect the encapsulated cargo and interacts with the surrounding biological environment.

The lipid bilayer of a Transfersome is not simply a standard lipid membrane. It is specifically and deliberately engineered through the incorporation of unique molecules called "edge activators." These

edge activators are strategically chosen to impart the Transfersome with its characteristic flexibility and deformability. This flexibility is essential, enabling the Transfersome to squeeze through narrow openings and navigate complex biological barriers, like the skin, more efficiently than conventional liposomes. These specialized properties are what make Transfersomes so promising for targeted drug delivery.

These novel carrier systems are typically prepared and utilized as semi-dilute suspensions. This means that the Transfersomes are dispersed in a liquid medium – they are not meant to be used as highly concentrated solutions or through an occlusive approach, like an ointment. Unlike some topical delivery vehicles, Transfersomes typically do not require an occlusive layer to enhance penetration. They are designed to penetrate effectively on their own.

The composition of Transfersomes is carefully controlled. Their primary components, by percentage, are:

- **10-25% Surfactants:** These surface-active agents are fundamental to the flexibility and deformability of the Transfersome bilayer. They help to reduce surface tension and allow the bilayer to bend and change shape as it moves through tissues. A higher percentage of surfactant corresponds to enhanced flexibility.
- **3-10% Alcohol:** An alcohol, commonly ethanol, is incorporated as a solvent. This helps to dissolve the lipids and edge activators during the preparation process, facilitating the formation of the bilayer structure. The alcohol also plays a role in the stability of the Transfersome system.
- **Hydrating Medium:** All these components are suspended in a hydrating medium, specifically saline phosphate buffer maintained at a pH range of 6.5-7. This buffer solution is physiologically compatible, ensuring that the Transfersomes and their cargo are stable and do not cause irritation when in contact with living tissue. The saline provides isotonicity to maintain cell integrity and the phosphate buffer provides pH stability **[1-3]**.



Figure 1: structure of transferosomes [4]

MECHANISM:

Transdermal drug delivery (TDD) typically relies on one of three main mechanisms:

The trans-appendageal route, also known as the shunt route, utilizes hair follicles and their associated sweat glands to create a continuous pathway across the stratum corneum (SC). This route offers a large surface area for solute diffusion. Factors like sweating and secretions from sebaceous and sweat glands influence permeation. However, hair follicles occupy a small fraction (approximately 0.1%) of the skin's surface area and therefore contribute minimally to overall TDD.

The intracellular route, also called the transcellular route, involves solute penetration through the SC by passing directly through the corneocytes. These are highly hydrated, keratin-containing dead cells, with the level of hydration being influenced by skin moisture and environmental temperature. This pathway is more suitable for hydrophilic solutes. Due to the lipid matrix surrounding these hydrated keratinocytes, the solute must undergo multiple partitioning events while traveling through the skin.

The intercellular route involves diffusion through the lipid matrix located between the corneocytes. This pathway represents a more tortuous route compared to the direct pathways mentioned before. As the drug progresses through the epidermal layers, and encounters a water gradient across the SC, multiple steps of partitioning and diffusion are necessary for it to reach the lower viable epidermis, dermis, and ultimately the systemic circulation **[4-8]**.

Advantages of Transferosomes:

- **Improved Drug Delivery:** Transferosomes, due to their flexible and deformable nature, significantly enhance the delivery of both small and large drug molecules.
- **Non-Invasive Administration:** This delivery method provides a non-invasive alternative to injections, which can improve patient adherence to treatment plans.

- **Precise Targeting:** Transferosomes can deliver drugs directly to the intended site within the skin, thus minimizing potential systemic side effects.
- **Versatile Drug Carriers:** The unique structure of transferosomes, incorporating both water-loving (hydrophilic) and water-repelling (hydrophobic) components, allows them to effectively transport a broad range of drug molecules regardless of their solubility.
- **Exceptional Deformability:** Transferosomes are incredibly flexible, allowing them to pass through narrow constrictions that are 5 to 10 times smaller than their own size without compromising their structure. This property is crucial for effective tissue penetration.
- **Reliable and Consistent Delivery:** The self-assembling nature and highly flexible membrane of transferosomes ensure consistent and dependable drug delivery both into and through the skin.
- **Superior Elasticity:** Transferosomes are far more elastic than conventional liposomes, enabling them to easily navigate the tight spaces within the stratum corneum and overcome skin penetration barriers by squeezing through the intracellular lipids.
- **Biocompatible and Efficient:** Because they are made of natural phospholipids, similar to liposomes, transferosomes have excellent biocompatibility and biodegradability. They also exhibit high encapsulation rates, achieving close to 90% entrapment for fat-soluble drugs.
- **Drug Protection and Sustained Release:** Transferosomes effectively protect encapsulated drugs from metabolic breakdown. They can also act as drug reservoirs, providing sustained and gradual drug release. These vesicles are suitable for delivering drugs both topically and systemically.
- **Enhanced Transdermal Delivery:** Overall, the complex lipid structure of transferosomes enhances the rate of drug permeation through the skin, enables prolonged drug release, and improves the targeting of active molecules **[9-11]**.

Challenges and Limitations:

- Transfersomes are susceptible to chemical breakdown due to their vulnerability to oxidative degradation, making them chemically unstable.
- The difficulty in obtaining highly purified natural phospholipids presents a challenge to the widespread use of transfersomes as drug delivery systems.
- Formulating transfersomes can be costly.
- Transfersomes are not ideal for delivering drugs that require high concentrations in the bloodstream.
- The rate at which transfersome molecules penetrate the skin is slow.
- Transfersomes are not suitable for administering high doses of medication.

- Their inherent vulnerability to oxidative degradation renders transfersomes susceptible to chemical instability **[12-15]**.

Transferosome Transport Mechanism:

1. **Surface Application:** Transferosomes are applied to the skin as a slightly diluted suspension, targeting the stratum corneum, the skin's outermost layer.
2. **Enhanced Skin Penetration:**
   - **Hydration:** The formulation's water content hydrates the skin, increasing its permeability for better transferosome penetration.
   - **Flexibility:** The presence of edge activators, such as surfactants like sodium cholate, sodium deoxycholate, span 80, and tween 80, imparts exceptional deformability to transferosomes. This allows them to squeeze through narrow skin pores and between cells without disruption.
3. **Cellular and Intercellular Passage:**
   - **Intercellular Pathway:** Transferosomes utilize their flexible lipid bilayer to navigate the complex path through the lipid matrix between skin cells.
   - **Transcellular Pathway:** Transferosomes can also penetrate directly through skin cells, maximizing drug delivery.
4. **Delivery to Deeper Layers:** As transferosomes move into the deeper skin layers, they release their drug payload. This enables the drug to reach systemic circulation if needed for whole-body effects.
5. **Controlled Drug Release:** The encapsulated drug is released in the deeper skin layers in a controlled, sustained manner, ensuring a long-lasting therapeutic benefit **[16-20]**.



Figure 2: The mechanism of action of transfersomes [21]

Table 1: Additives Used in Transferosome Formulations [22 - 24]

Ingredient Type	Examples	Functions
Phospholipids	Soya phosphatidylcholine, Egg phosphatidylcholine, Dipalmityl phosphatidylcholine, Distearyl phosphatidylcholine, Phospholipin, Cholesterol, Soyalecithin, Phosphatidylserine, Phosphatidic acid, Dioleoyl phosphatidylethanolamine, 1,2-dioleoyl-3-trimethyl ammonium-propane-CDOTAP, Labrafac, Olive oil, Soybean oil, Stearic acid, Capmul MCM, Arachis oil, Compritol 888ATO, Precirol ATO 5, Captex 200, Labrafac Lipophile WL1349	Essential for forming the vesicle structure of transferosomes.
Surfactants	Sodium cholate, Sodium deoxy cholate, Tween 80, Span 80, Stearylamine, Dodecyltrimethyl ammonium bromide, Cetylpyridinium chloride monohydrate, Sodium lauryl sulfate, Tween 20, Gelucire 44/14, Span 20, Labrasol, Cremophor EL, Labrafil	Enhance flexibility and deformability of the transferosome membrane, aiding in passage through narrow spaces.
Alcohols	Ethanol, Methanol	Used as solvents in the formulation process.
Dyes	Rhodamine-123, Rhodamine-DHPE, Fluorescein-DHPE, Nile red, 6-Carboxyfluorescein	Incorporated for visualization and tracking of transferosomes in confocal scanning laser microscopy (CSLM) studies.
Buffering Agents	Saline phosphate buffer (pH 6.5), 7% v/v ethanol, Tris buffer (pH 6.5)	Serve as hydrating media to maintain a stable environment for transferosome formulations.

METHODS OF PREPARATION OF TRANSFEROSOMES [26-35]

Transferosomes can be prepared using several techniques, each designed to optimize vesicle formation, drug encapsulation, and stability. The most commonly used methods include the Shaking Method, Thin Film Hydration, Rotary Film Evaporation, Vortexing-Sonication, Reverse Phase Evaporation, Ethanol Injection, Microfluidic, Freeze-Thaw, Spray Drying, and Supercritical Fluid Methods. Below is a detailed description of each method:

1. Shaking Method for Transferosomes

The shaking method is a simple and effective approach to preparing transferosomes, enhancing their ultra-deformability for improved skin penetration.

Steps:

1. **Lipid Solution Preparation:**
   - Dissolve phospholipids (e.g., soya phosphatidylcholine) and edge activators (e.g., sodium cholate, sodium deoxycholate, Span 80, Tween 80) in an organic solvent such as chloroform or methanol.
2. **Thin Film Formation:**
   - Remove the organic solvent under reduced pressure using a rotary evaporator, leaving a thin lipid film on the inner surface of a round-bottom flask.
3. **Lipid Film Hydration:**
   - Hydrate the lipid film with an aqueous solution (e.g., phosphate-buffered saline containing the drug).

- Gently swirl the flask to evenly hydrate the film and form multilamellar vesicles.

4. **Transferosome Formation via Shaking:**
   - Shake the mixture vigorously, manually or mechanically, for 30–60 minutes to form transferosomes.
5. **Size Reduction (Optional):**
   - Use sonication or extrusion through polycarbonate membranes to refine vesicle size.
6. **Storage:**
   - Store in a suitable container under refrigeration for stability.

Advantages:

- Simple and cost-effective.
- Scalable for larger batches.
- Produces highly flexible transferosomes.

2. Microfluidic Method

This technique utilizes microfluidic chips to precisely mix lipid and aqueous phases for uniform transferosome production.

Steps:

- Lipids and surfactants are dissolved in a solvent and injected into a microfluidic device.
- The aqueous phase containing the drug is introduced at controlled flow rates.
- Rapid mixing leads to spontaneous vesicle formation.

Advantages:

- Produces highly uniform transferosomes.
- Scalable and reproducible.
- Reduces solvent waste.

3. Freeze-Thaw Method

A technique used to improve vesicle stability and drug encapsulation efficiency.

Steps:

- Transferosomes are initially prepared using a conventional method.
- The vesicle suspension undergoes repeated cycles of freezing and thawing to enhance drug retention.

Advantages:

- Improves vesicle stability.
- Increases drug encapsulation efficiency.
- Enhances vesicle fusion properties.

4. Spray Drying Method

This technique converts transferosomes into a dry powder form for enhanced storage stability.

Steps:

- Transferosome suspension is sprayed into a drying chamber.
- Solvent is rapidly evaporated, forming dry transferosomal powder.

Advantages:

- Improves long-term stability.
- Easier handling and transportation.
- Rehydratable before use.

5. Supercritical Fluid Method

This method uses supercritical CO_2 for solvent removal, producing highly stable vesicles.

Steps:

- Lipids and edge activators are dissolved in an organic solvent.
- Supercritical CO_2 is introduced to extract the solvent and promote vesicle formation.

Advantages:

- Eliminates toxic solvents.
- Produces highly stable vesicles.
- Environmentally friendly.

6. Thin Film Hydration Method

This technique is widely used for preparing transferosomes, yielding vesicles with properties ideal for skin penetration.

Steps:

1. **Lipid Solution Preparation:**
   - Dissolve phospholipids and edge activators in an organic solvent like chloroform or methanol.
2. **Thin Lipid Film Formation:**
   - Transfer the lipid solution to a round-bottom flask and remove the solvent using a rotary evaporator.
3. **Hydration of the Lipid Film:**
   - Add an aqueous buffer solution containing the drug.
   - Swirl gently to hydrate the lipid film.
4. **Vesicle Size Reduction:**
   - Sonicate or extrude the MLVs to obtain transferosomes.
5. **Storage:**
   - Store under controlled conditions.

Advantages:

- Precise control over vesicle size.
- High encapsulation efficiency.
- Suitable for industrial-scale production.



Figure 3: Thin Film Hydration Method

7. Rotary Film Evaporation Method

Also known as the hand-shaking process, this method is commonly used for multilamellar vesicle (MLV) preparation.

Steps:

- Dissolve phospholipids and surfactants in an organic solvent mixture.
- Apply rotary evaporation to form a thin lipid film.
- Hydrate with an aqueous drug solution.
- Use extrusion or sonication to refine vesicle size.

Advantages:

- Produces stable multilamellar vesicles.
- Suitable for large-scale production.
- High drug encapsulation efficiency.



Figure 4: Rotary Film Evaporation Method

8. Vortexing-Sonication Method

This method produces highly uniform transferosomes using vortex mixing and sonication.

Steps:

- Dissolve phospholipids, edge activators, and the drug in a phosphate buffer.
- Vortex the mixture to form a milky suspension.
- Sonicate and extrude through polycarbonate membranes.

Advantages:

- Produces uniform and small-sized transferosomes.
- Rapid and efficient vesicle formation.
- Suitable for heat-sensitive drugs.



Figure 5: Vortexing-Sonication Method

9. Reverse Phase Evaporation Method

This method is effective for high drug-loading efficiency.

Steps:

- Dissolve lipids in an organic solvent.
- Introduce an aqueous drug-containing medium while purging with nitrogen gas.
- Sonicate and remove the organic solvent under reduced pressure.
- Remove non-encapsulated drug via centrifugation or dialysis.

Advantages:

- High drug-loading efficiency.
- Suitable for hydrophilic and lipophilic drugs.
- Produces stable vesicles with controlled release properties.



Figure 6: Reverse Phase Evaporation Method

10. Ethanol Injection Method

Ensures rapid vesicle formation with controlled particle size.

Steps:

- Dissolve phospholipids, edge activators, and lipophilic drugs in ethanol.
- Dissolve hydrophilic drugs separately in a phosphate buffer.
- Inject the ethanolic solution into the aqueous phase with stirring.
- Use a vacuum evaporator to remove ethanol.
- Sonicate for particle size reduction.

Advantages:

- Produces small, stable vesicles.
- Efficient for drug encapsulation.
- Quick and reproducible method.

Each of these methods offers distinct advantages, allowing researchers to select the best approach based on drug properties, required vesicle size, and intended application.



Figure 7: Ethanol Injection Method

Characterization of Transferosomes [35-39]:

Vesicle Size Distribution and Zeta Potential

- Vesicle size, size distribution, and zeta potential are determined using a Malvern Zetasizer with a Dynamic Light Scattering system.

Vesicle Morphology

- Vesicle diameter is measured using photon correlation spectroscopy or dynamic light scattering (DLS). Samples are prepared in distilled water, filtered through a 0.2 mm membrane, and diluted with filtered saline before DLS measurements. Transfersome vesicles can be visualized using techniques like TEM (transmission electron microscopy) or phase contrast microscopy. Vesicle stability is assessed by monitoring size and

structure over time using DLS for mean size changes and TEM for structural observations.

Vesicle Concentration

- Determining the number of vesicles per cubic millimeter is important for optimizing formulation composition and processing variables. Non-sonicated transfersome formulations are diluted five-fold with 0.9% sodium chloride solution. The concentration is then determined using a hemocytometer and optical microscope. The following formula is used: Total vesicles per cubic mm = (Total vesicles counted × dilution factor × 4000) / Total squares counted.

Entrapment Efficiency

- Entrapment efficiency, expressed as the percentage of drug entrapped, is determined by separating unentrapped drug using a mini-column centrifugation method. Vesicles are then disrupted using 0.1% Triton X-100 or 50% n-propanol. The entrapment efficiency is calculated as follows: Entrapment efficiency = (Amount of drug entrapped / Total amount of drug added) × 100.

Drug Content

- Drug content is determined through instrumental analytical methods, such as a modified high-performance liquid chromatography (HPLC) method. This utilizes a UV detector, column oven, autosampler, pump, and a computerized analysis program tailored to the pharmacopoeial drug's analytical method.

Turbidity Measurement

- Turbidity, a measure of cloudiness in an aqueous solution, is determined using a nephelometer.

Degree of Deformability/Permeability

- Deformability and permeability are critical characteristics of transfersomes. Deformability is assessed against pure water as a standard. The transfersome preparation is passed through a series of micro porous filters with pore sizes ranging from 50 nm to 400 nm. Particle size and size distribution are measured after each passage using dynamic light scattering (DLS).

Penetration Ability

- The penetration ability of transfersomes is evaluated using fluorescence microscopy.

Occlusion Effect

- While occlusion can be beneficial for traditional topical formulations, it can be detrimental for elastic vesicles like transfersomes. The primary driving force for transfersome permeation through the skin is hydrotaxis (water movement) from the dry surface to water-rich deeper regions. Occlusion inhibits water evaporation from the skin, affecting these hydration forces.

Surface Charge Density

- Surface charge and charge density of transfersomes are determined using a zeta sizer.

***In Vitro* Drug Release**

- *In vitro* drug release studies are performed to determine permeation rate, time to steady-state permeation, and permeation flux. These

studies help optimize formulations before conducting more costly *in vivo* trials. To determine drug release, transfersome suspensions are incubated at 32°C, with samples taken at different time points. The free drug is separated using mini-column centrifugation. The amount of drug released is calculated indirectly using the initial entrapped amount as 100% (at time zero).

***In Vitro* Skin Permeation Studies**

- *In vitro* skin permeation studies are carried out using a modified Franz diffusion cell with a 50 mL receiver compartment and a 2.50 cm² effective diffusion area. Goat skin, obtained from a slaughterhouse and prepared by removing abdominal hair, is used as the membrane, with phosphate buffer solution (pH 7.4) used as the receiving medium.

Physical Stability

- To assess physical stability, the initial drug entrapment percentage is determined in sealed glass ampoules. These ampoules are stored at 4 ± 2°C. Samples from each ampoule are then analyzed every 30 days to measure drug leakage. The percent drug loss is calculated by using the initial drug entrapment as 100%.

Applications of Transfersomes [40-45]

1. **Transdermal Drug Delivery:**
   - **Enhanced Skin Penetration:** Transfersomes exhibit superior skin penetration compared to conventional vesicular systems, making them ideal for delivering drugs through the skin.
   - **Sustained Release:** They enable controlled and sustained drug release, which is particularly advantageous for the management of chronic conditions.
2. **Topical Medications:**
   - **Treatment of Skin Conditions:** Transfersomes are employed to deliver treatments for various skin disorders including eczema, psoriasis, and acne.
   - **Localized Pain Relief:** They allow for the targeted delivery of analgesics, providing localized pain relief without the systemic side effects of oral medications.
3. **Vaccine Delivery:**
   - **Edible Vaccines:** Transfersomes show promise in the development of edible vaccines, offering a more convenient administration method and the potential to increase vaccination coverage.
   - **Mucosal Vaccines:** They are also suitable for delivering vaccines to mucosal surfaces, potentially eliciting a more robust immune response at the site of pathogen entry.
4. **Ocular Drug Delivery:**
   - **Eye Drop Formulations:** Transfersomes can be incorporated into eye drops to improve the delivery of drugs for treating conditions like glaucoma and eye infections.
   - **Reduced Administration Frequency:** They provide sustained drug release, reducing the need for frequent application of eye drops.
5. **Hormone Replacement Therapy:**
   - **Non-Invasive Delivery:** Transfersomes can deliver hormones like testosterone and

estrogen, offering a non-invasive approach to hormone replacement therapy.

6. **Cosmetics and Personal Care:** (Note: This section was originally combined with anticancer use, I separated for clarity)

- Transfersomes are being investigated for specialized cosmetic and personal care applications, such as delivering active ingredients directly to target skin areas.

7. **Cancer Therapy:**

- **Targeted Chemotherapy:** Transfersomes can carry anticancer drugs directly to tumor sites, minimizing systemic toxicity and enhancing treatment effectiveness.
- **Precision Targeting:** They can be engineered to target specific types of cancer cells, increasing the precision of cancer treatment.

Drug Candidates Suitable for TransferosomalDelivery [46-50]

Transferosomes are highly flexible vesicular carriers that enhance the transdermal and targeted delivery of various drugs. They are particularly useful for drugs with low skin permeability, poor bioavailability, or requiring controlled release. Below is a list of drug candidates suitable for transferosomal delivery:

1. Anti-Inflammatory Drugs

- **Diclofenac Sodium** – Used for arthritis and musculoskeletal pain management.
- **Ketoprofen** – Effective for osteoarthritis and joint inflammation.
- **Ibuprofen** – Suitable for topical treatment of pain and inflammation.
- **Celecoxib** – Selective COX-2 inhibitor for rheumatoid arthritis and osteoarthritis.
- **Meloxicam** – Long-acting NSAID for chronic inflammatory conditions.
- **Diclofenac Sodium** – Used for arthritis and musculoskeletal pain management.
- **Ketoprofen** – Effective for osteoarthritis and joint inflammation.
- **Ibuprofen** – Suitable for topical treatment of pain and inflammation.

2. Hormonal Drugs

- **Testosterone** – Used in hormone replacement therapy.
- **Estradiol** – Delivered transdermally for menopausal hormone therapy.
- **Insulin** – Investigated for non-invasive diabetes management.

3. Anticancer Drugs

- **Lapatinib** – Used in breast cancer treatment; transferosomal delivery improves solubility and bioavailability.
- **Nintedanib** – A tyrosine kinase inhibitor for lung fibrosis and cancer; transferosomes enhance systemic absorption.

- **Tamoxifen** – Used for breast cancer treatment.
- **5-Fluorouracil (5-FU)** – Topical chemotherapy agent for skin cancer.
- **Curcumin** – Explored for its anti-cancer properties.
- **Doxorubicin** – An anthracycline antibiotic used for multiple cancers; transferosomes help reduce cardiotoxicity.
- **Paclitaxel** – Used for ovarian, breast, and lung cancers; transferosomal delivery improves solubility and targeted therapy.
- **Methotrexate** – Applied in leukemia, lymphoma, and rheumatoid arthritis; transferosomes enhance targeted drug delivery.
- **Gefitinib** – EGFR inhibitor used in non-small cell lung cancer treatment.
- **Erlotinib** – Used in targeted therapy for lung and pancreatic cancers.
- **Imatinib** – Effective for chronic myeloid leukemia and gastrointestinal stromal tumors.
- **Lapatinib** – Used in breast cancer treatment; transferosomal delivery improves solubility and bioavailability.
- **Nintedanib** – A tyrosine kinase inhibitor for lung fibrosis and cancer; transferosomes enhance systemic absorption.

- **Tamoxifen** – Used for breast cancer treatment.
- **5-Fluorouracil (5-FU)** – Topical chemotherapy agent for skin cancer.
- **Curcumin** – Explored for its anti-cancer properties.
- **Doxorubicin** – An anthracycline antibiotic used for multiple cancers; transferosomes help reduce cardiotoxicity.
- **Paclitaxel** – Used for ovarian, breast, and lung cancers; transferosomal delivery improves solubility and targeted therapy.
- **Methotrexate** – Applied in leukemia, lymphoma, and rheumatoid arthritis; transferosomes enhance targeted drug delivery.
- **Lapatinib** – Used in breast cancer treatment; transferosomal delivery improves solubility and bioavailability.
- **Nintedanib** – A tyrosine kinase inhibitor for lung fibrosis and cancer; transferosomes enhance systemic absorption.
- **Tamoxifen** – Used for breast cancer treatment.
- **5-Fluorouracil (5-FU)** – Topical chemotherapy agent for skin cancer.
- **Curcumin** – Explored for its anti-cancer properties.

4. Antifungal and Antimicrobial Agents

- **Miconazole Nitrate** – Used for fungal infections.
- **Itraconazole** – Effective in treating systemic fungal infections.
- **Clindamycin** – Used for bacterial skin infections and acne treatment.

5. Cardiovascular Drugs

- **Timolol Maleate** – Used in the treatment of glaucoma.
- **Telmisartan** – Explored for transdermal hypertension management.
- **Propranolol** – A beta-blocker used for hypertension and arrhythmias; transferosomes improve controlled release.
- **Amlodipine** – A calcium channel blocker for hypertension; transferosomal formulation enhances bioavailability.
- **Atenolol** – A selective beta-blocker for hypertension and angina.
- **Nitroglycerin** – Used for angina pectoris; transdermal delivery improves sustained effect.
- **Timolol Maleate** – Used in the treatment of glaucoma.
- **Telmisartan** – Explored for transdermal hypertension management.
- **Propranolol** – A beta-blocker used for hypertension and arrhythmias; transferosomes improve controlled release.
- **Amlodipine** – A calcium channel blocker for hypertension; transferosomal formulation enhances bioavailability.
- **Timolol Maleate** – Used in the treatment of glaucoma.
- **Telmisartan** – Explored for transdermal hypertension management.

6. Dermatological and Cosmetic Applications

- **Tretinoin** – Used in anti-aging and acne treatment.
- **Resveratrol** – Investigated for its antioxidant and skin-rejuvenating properties.
- **Capsaicin** – Used for pain relief in arthritis and neuropathic conditions.

7. Vaccine and Peptide Delivery

- **Insulin** – Potential use for diabetes management.
- **Edible Vaccines** – Under research for needle-free immunization.
- **COVID-19 Peptide Vaccines** – Investigated for enhanced mucosal and transdermal vaccine delivery.
- **Hepatitis B Vaccine** – Transferosomal formulations studied for improved immune response.
- **Influenza Vaccine** – Potential application for needle-free vaccine delivery via skin absorption.

- **HPV Vaccine** – Studied for non-invasive immunization against cervical cancer.
- **Rabies Vaccine** – Investigated for potential transdermal administration.
- **Insulin** – Potential use for diabetes management.
- **Edible Vaccines** – Under research for needle-free immunization.
- **COVID-19 Peptide Vaccines** – Investigated for enhanced mucosal and transdermal vaccine delivery.
- **Hepatitis B Vaccine** – Transferosomal formulations studied for improved immune response.
- **Influenza Vaccine** – Potential application for needle-free vaccine delivery via skin absorption.
- **Insulin** – Potential use for diabetes management.
- **Edible Vaccines** – Under research for needle-free immunization.

These drug candidates benefit from transferosomal delivery due to enhanced bioavailability, reduced side effects, and improved patient compliance. Transferosomes represent a promising approach for various therapeutic applications, expanding the potential of non-invasive and controlled drug administration.

Table 2: Transferosome-Based Transdermal Drug Delivery Systems

S. No	Author	Drug	Lipids	Surfactants	Conclusion	Reference
1	Jadupati Malakar	Insulin	Soya lecithin, Cholesterol	Tween 80, Sodium deoxycholate	Transferosomal gel for insulin delivery shows potential in treating insulin-dependent diabetes mellitus by maintaining lower blood glucose levels.	[51,52]
2	Saeed Ghanbauzadh, Sanam Arami	Diclofenac sodium	Soya lecithin, Cholesterol	Span 80	Transferosomes enhance Diclofenac sodium permeation through rat skin.	[53,54]
3	Marwa H. Abdallah	Ibuprofen	Phospholipan	Tween 80	Developed transferosomal gel demonstrated excellent anti-psoriatic activity.	[55,56]
4	Lovely Chaurasia	Ketoconazole	Phosphatidylcholine, Cholesterol	Tween 80, Span 80	Transferosomal gel effectively delivers ketoconazole for acne treatment with deeper skin penetration.	[57,58,59]
5	Moawad F.A	Tizanidine HCl	Phosphatidylcholine, Cholesterol	Span 80, Sodium deoxycholate, Polyoxyethylene lauryl ether	Prolonged drug release improves efficacy in spasticity treatment.	[60,61]
6	Eleesha Sana	Curcumin	Phospholipan 90G	Tween 80	Curcumin-loaded transferosomal gel enhances drug delivery to arthritic dermal tissue through topical application.	[62,63]
7	Iqrar Ali Alvi	5-Fluorouracil	-	-	Vesiculization enhances topical delivery and cytotoxic effects of 5-Fluorouracil.	[64,65]
8	Raquel Fernandez-Garcia	Ketoprofen	Phosphatidylcholine	Sodium deoxycholate, Tween 80, Span 80	Transferosomal gel formulation for osteoarthritis treatment with minimal skin and subcutaneous tissue side effects.	[66,67]
9	Pey-Shiuan Wu	Resveratrol	Phosphatidylcholine	Non-ionic edge activator, 5% ethanol	Transfersomes show potential as a formulation in cosmetic, food, and pharmaceutical applications.	[68,69]

10	Shaimaa M. Badr-Eidin	Sildenafil Citrate	Phosphatidylcholine	Span 80, Span 60	Enhanced bioavailability and extended drug absorption using optimized transferosomal films.	[70,71]
11	Arthritis Preeti	Celecoxib	Lecithin	Tween 80, Span 80, Sodium cholate	Transferosomal gel proved effective for rheumatoid arthritis treatment.	[72,73]
12	Sureewanduangjit	Meloxicam	Cholesterol	Sodium cholate, Diacetyl phosphate	MX-loaded transferosomes show potential as a transdermal therapeutic agent.	[74,75]
13	Ved Prakash	Tacrolimus	Phosphatidylcholine	Sodium deoxycholate	Transferosomes demonstrated superior antipsoriatic activity.	[76,77]
14	Khomendra Kumar Serwa	Capsaicin	Phosphatidylcholine	Tween 80	Capsaicin-loaded transferosomes showed anti-arthritic activity when applied topically in arthritic rats.	[78,79]
15	Amit Bhatia	Tamoxifen	Lecithin	Tween 80	Potential application in psoriasis management.	[80,81]
16	Samin Amin	Telmisartan	Soybean phosphatidylcholine, Dipalmitoyl phosphatidylglycerol	Sodium deoxycholate, Tween 80, Span 60	Skin irritation issues observed in transferosomal formulation.	[82,83]
17	Mohammad S.	Raloxifene HCl	Phospholipan 90G	Tween 80	Transferosomal formulation with sorbitan 80 showed promise for transdermal application.	[84,85]
18	Andreia Ascenso	Tretinoin	Phosphatidylcholine	Tween 80	15% tretinoin formulation showed 2-fold higher permeation compared to 20% formulation.	[86,87]
19	Ahmed A.H. Abdellatif	Clindamycin	-	-	Transferosomal gel resulted in 1.2-fold higher permeation than control gel.	[88,89]
20	Wang J	Sinomenine	Phosphatidylcholine	Sodium deoxycholate	Transferosomes achieved an 8-fold higher steady-state concentration compared to liposomes.	[90,91]

Table 3: Marketed Transferosomal Drug Formulations [91-100]

S. No.	Product Name	Drug	Indication	Manufacturer
1	Daktarin	Miconazole Nitrate	Antifungal	Johnson & Johnson Pvt. Ltd.
2	Flexiseq	Ketoprofen	Osteoarthritis	Ascension Healthcare PLC
3	Voltaren	Diclofenac Sodium	NSAID	GlaxoSmithKline
4	Sporanox	Itraconazole	Antifungal	Johnson & Johnson Pvt. Ltd.
5	Timoptol-XE	Timolol Maleate	Non-Selective Beta-Adrenergic Receptor Antagonist	Merck & Co.
6	Diractin	Ketoprofen	Osteoarthritis	Novartis Pharmaceuticals

CONCLUSION

Transfersomes are a groundbreaking advance in transdermal drug delivery, offering distinct advantages over traditional methods. Their deformability, self-optimization, biocompatibility, and high permeation capacity enable efficient drug transport across the skin. Although challenges like stability, cost, and permeation rate variability remain, ongoing research is focused on addressing these limitations to fully realize the potential of Transfersomes. Their ability to deliver diverse drugs and target specific areas makes them a highly promising platform for future pharmaceutical and biomedical advancements. As our understanding of Transfersome technology deepens, its influence on drug delivery is poised to expand, potentially revolutionizing treatments for numerous diseases.

REFERENCES

[1] Cevc G. Material transport across permeability barriers by means of lipid vesicles In: Lipowsky R, editor. Handbook of physics of biological systems. Amsterdam: Elsevier Science. 1994; Vol. I. Vol. 9 pp : 441–466.

[2] R., Parashar T, Vishal Singh S., Singh G., Tyagi S., Pateal C., Gupta A., "Transfersomes: A Novel Tool For Transdermal Drug Delivery System" International Journal of research and Development in Pharmacy and Life Sciences, 2013; 2(2):309-316

[3] Walve JR, Bakliwal SR, Rane BR, Pawar SP. Transfersomes : A surrogated carrier for transdermal drug delivery system. International Journal of Applied Biology and Pharmaceutical Technology. 2011; 2 (1) : 201-214.

[4] Pola, K. K., & Kumar Rada. In Transdermal Drug Delivery. International Journal of Applied Pharmaceutics, *15*(3), 28–34. https://doi.org/10.22159/ijap.2023v15i3.46785.Rai

[5] S, Pandey V, Rai G. Transfersomes as versatile and flexible Patel S, Ismail Y, Singh S, Rathi S, Shakya S, Patil SS, Bumrela S, Jain PC, Goswami P, Singh S. Recent Innovations and Future Perspectives in Transferosomes for Transdermal Drug Delivery in

[6] Sapkota R, Dash AK. Liposomes and transferosomes: a breakthrough in topical and transdermal delivery. Ther Deliv. 2021 Feb;12(2):145-158. doi: 10.4155/tde-2020-0122. Epub 2021 Feb 15. PMID: 33583219.

[7] Rajan R, Jose S, Mukund VP, Vasudevan DT. Transferosomes - A vesicular transdermal delivery system for enhanced drug permeation. J Adv Pharm Technol Res. 2011 Jul;2(3):138-43. doi: 10.4103/2231-4040.85524.

[8] Chacko IA, Ghate VM, Dsouza L, Lewis SA. Lipid vesicles: A versatile drug delivery platform for dermal and transdermal applications. Colloids Surf B Biointerfaces. 2020 Nov; 195: 111262. doi: 10.1016/j.colsurfb.2020.111262. Epub 2020 Jul 17. PMID: 32736123.

[9] J. Rajkumar. *et al*. A new approach transdermal drug delivery using transferosomes _ Based nano encapsulation. Asian journal of pharmaceutical research and development 22,10(1) 64_70. DOI:http://dx.doi.org/10.22270/ajprd.v10i.1082

[10] Schatzlein A, Cevc G: Non-Uniform Cellular Packing of The Stratum Corneum and Permeability Barrier Function of Intact Skin: A High-Resolution Confocal Laser Scanning Microscopy Study Using Highly

Deformable Vesicles (Transferosomes). Br. J. Dermatol. 1998; (138):583-598.

[11] Ahmed, A.; Ghourab, M.; Gad, S.; Qushawy, M. The Application of Plackett-Burman Design and Response Surface Methodology For Optimization Of Formulation Variables To Produce Piroxicam Niosomes. Int. J. Drug Dev. Res. 2013, 5, 121–130.

[12] Bouwstra, J. A., Honeywell-Nguyen, P. L., Gooris, G. S., & Ponec, M. (2003) – Structure of the skin barrier and its modulation by vesicular formulations. Progress in Lipid Research, 42(1), 1-36.

[13] Jain S., Jain P. Transferosomes: A novel vesicular carrier for enhanced transdermal delivery: development, characterization and performance evaluation, Drug Dev. Ind. Pharm. 2003; 29:1013-1026

[14] Gregor C, Dieter G, Juliane S, Andreas S, Gabriele B, "Ultra-flexible vesicles, Transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin", Biophysica Acta, 1998, 1368:201-215.

[15] Maghraby EI, Williams GM, Barry BW, "Skin delivery of oestradiol from lipid vesicles: importance of liposome structure", Int. J. Pharma, 2000, 204 (1-2):159-69.

[16] Kumar A, Nayak A, Ghatuary SK, Dasgupta S, Jain AP, Transferosome: A recent approach for transdermal drug delivery, Journal of Drug Delivery and Therapeutics. 2018; 8(5-s):100-104 DOI: http://dx.doi.org/10.22270/jddt.v8i5-s.1981.

[17] Opatha SAT, Titapiwatanakun V, Chutoprapat R. Transfersomes: A Promising Nanoencapsulation Technique for Transdermal Drug Delivery. Pharmaceutics. 2020 Sep 9;12(9):855. doi: 10.3390/pharmaceutics12090855. PMID: 32916782; PMCID: PMC7559928.

[18] Chaurasiya P., Ganju E., Upmanyu N., Ray S.K., Jain P. Transfersomes: A novel technique for transdermal drug delivery. J. Drug Deliv. Ther. 2019; 9: 279–285. doi: 10.22270/jddt.v9i1.2198.

[19] Elsayed M.A., Abdallah O.Y., Naggar V.F., Khalafallah N.M. Lipid vesicles for skin delivery of drugs: Reviewing three decades of research. Int. J. Pharm. 2007;332:1–16. doi: 10.1016/j.ijpharm.2006.12.005.

[20] Touitou E., Junginger H.E., Weiner N.D., Nagai T., Mezei M. Liposomes as carriers for topical and transdermal delivery. J. Pharm. Sci. 1994;83:1189–1203. doi: 10.1002/jps.26008309

[21] Baroli, B. (2010) – Penetration of nanoparticles and nanomaterials in the

skin: Fiction or reality? Journal of Pharmaceutical Sciences, 99(1), 21-50

[22] Jafari A, Daneshamouz S, Ghasemiyeh P, Mohammadi-Samani S. Ethosomes as dermal/transdermal drug delivery systems: applications, preparation and characterization. J Liposome Res. 2023 Mar;33(1):34-52. doi: 10.1080/08982104.2022.2085742. Epub 2022 Jun 13. PMID: 35695714..

[23] Zorec B, Zupančič Š, Kristl J, Pavšelj N. Combinations of nanovesicles and physical methods for enhanced transdermal delivery of a model hydrophilic drug. Eur J Pharm Biopharm. 2018 Jun;127:387-397. doi: 10.1016/j.ejpb.2018.03.008. Epub 2018 Mar 23. PMID: 29581043.

[24] Sala M, Diab R, Elaissari A, Fessi H. Lipid nanocarriers as skin drug delivery systems: Properties, mechanisms of skin interactions and medical applications. Int J Pharm. 2018 Jan 15;535(1-2):1-17. doi: 10.1016/j.ijpharm.2017.10.046. Epub 2017 Oct 27. PMID: 29111097.

[25] Chacko IA, Ghate VM, Dsouza L, Lewis SA. Lipid vesicles: A versatile drug delivery platform for dermal and transdermal applications. Colloids Surf B Biointerfaces. 2020 Nov; 195: 111262. doi: 10.1016/j.colsurfb.2020.111262

[26] Shin SC, Lee JW, Yang KH, Lee CH. Preparation and evaluation of bioadhesive benzocaine gels for enhanced local anesthetic effects. Int J Pharm. 2003 Jul 9;260(1):77-81. doi: 10.1016/s0378-5173(03)00256-4. PMID: 12818812.

[27] Singodia D, Gupta GK, Verma A, Singh V, Shukla P, Mishra P, *et al*. Development and performance evaluation of amphotericin B transferosomes against resistant and sensitive clinical isolates of visceral leishmaniasis. J Biomed Nanotechnol. 2010; 6: 293-302

[28] Prasurjya Jyoti Sarmah, *et al*. Transfersomes Based Transdermal Drug Delivery: An Overview. International Journal of Advances in Pharmaceutical Research, IJAPR /Dec. 2013/ Vol. 4 /Issue 12 /2555 – 2563.

[29] Opatha, S.A.T.; Titapiwatanakun, V.; Chutoprapat, R. Transfersomes: A Promising Nanoencapsulation Technique for Transdermal DrugDelivery. Pharmaceutics **2020**, *12*, 855. https://doi.org/10.3390/pharmaceutics12090855.

[30] Elsayed, M. M. A., Abdallah, O. Y., Naggar, V. F., & Khalafallah, N. M. (2006). Deformable liposomes and ethosomes as carriers for skin delivery of ketotifen. International Journal of Pharmaceutics, 322(1-2), 60-66.

[31] Gupta A, Aggarwal G, Singla S, Arora R. Transfersomes: a novel vesicular carrier for enhanced transdermal delivery of sertraline: development, characterization, and performance evaluation. Sci Pharm. 2012 Oct-Dec;80(4):1061-80. doi: 10.3797/scipharm.1208-02.

[32] Hofland HE, Bouwstra JA, Boddé HE, Spies F, Junginger HE. Interactions between liposomes and human stratum corneum in vitro: freeze fracture electron microscopical visualization and small angle X-ray scattering studies. Br J Dermatol. 1995 Jun;132(6):853-66. doi: 10.1111/j.1365-2133.1995.tb16940.x.

[33] Yadav, Jaydeep. (2011). Transferosomes: An Emerging Tool For Transdermal Drug Delivery. International Journal of Research in Pharmaceutical Sciences. 2. 735-741.

[34] Sunitha Reddy M, Transferosomes– A Novel Drug Delivery System: A Review, J. Global Trends Pharm Sci, 2020; 11 (4): 8761 – 8766

[35] Muneera Jasmin K P, et.al , Transferosomes For Effective Transdermal Drug Delivery , Int. J. Pharm. Sci. Rev. Res., ISSN: 0976 – 044X, 84(4) - April 2024, DOI: 10.47583/ijpsrr.2024.v84i04.002

[36] Madhumitha. V, S. Sangeetha. Transfersomes: A Novel Vesicular Drug Delivery System for Enhanced Permeation through Skin. Research J. Pharm. and Tech 2020; 13(5):2493-2501. doi: 10.5958/0974-360X.2020.00445.X

[37] Solanki, Dharmendra & Kushwah, Lalit & Chouhan, Vicky & Motiwale, Mohit. (2016). "Transferosomes-A Review". World Journal of Pharmacy and Pharmaceutical Sciences. 5. 435-449. 10.20959/wjpps201610-7845.

[38] Jain, S., Jain, P., Umamaheshwari, R. B., & Jain, N. K. (2003). Transfersomesa novel vesicular carrier for enhanced transdermal delivery: Development, characterization, and performance evaluation. Drug Development and Industrial Pharmacy, 29(9), 1013-1026.

[39] El ZaafaranyGM , Awad GAS, Holayel SM, Mortada ND. Role of edge activators and surface charge in developing ultra-deformable vesicles with enhanced skin delivery. International Journal Pharm. 2010; 397 : 164-172.

[40] Verma, P., & Pathak, K. (2012). Therapeutic applications of transferosomes: A review. International Journal of Pharmaceutical Sciences and Research, 3(4), 688-700.

[41] Ashok K, Kumar AR, Nama S, Brahmaiah B, Desu PK, Rao CB. Sphingosomes: a novel vesicular drug delivery system. International Journal of

Pharmaceutical Research and Bio-Science. 2013;2(2):305-12.

[42] Dhadwal A, Sharma DR, Pandit V, Ashawat MS, Kumar P. Cubosomes: A Novel Carrier for Transdermal Drug Delivery. J Drug Deliv Ther. 2020;10:123–30.

[43] Fernández-García R, Lalatsa A, Statts L, Bolás-Fernández F, Ballesteros MP, Serrano DR. Transferosomes as nanocarriers for drugs across the skin: Quality by design from lab to industrial scale. Int J Pharm. 2020; 573: 118817.

[44] Solanki D, Kushwah L, Motiwale M, Chouhan V. Transferosomes-a review. World Journal of Pharmacy and Pharmaceutical Sciences. 2016; 5: 435-49.

[45] Priyanka R., Shipra D., "Transferosomes: A Novel Carrier for Transdermal Drug Delivery System" International Journal Of pharmacy & Technology, April-2012; 4(1): 1854-1865

[46] Chandrakala podili, S. Firoz, A Review on Transferosomes for Transdermal Drug Delivery, Journal of Global Trends in Pharmaceutical Sciences, 2014, 5(4): 2118 –2127.

[47] Shubhra Rai, Vikas Pandey, and Gopal Rai, Transfersomes as versatile and flexible nano-vesicular carriers in skin cancer therapy: the state of the art, Nano Reviews & Experiments, 2017, 8:1, 1325708.

[48] Priyanka Chaurasiya, Eisha Ganju, Neeraj Upmanyu, Sudhir Kumar Ray, Prabhat Jain, Transfersomes: a novel technique for transdermal drug delivery, Journal of Drug Delivery and Therapeutics, 2019, 9(1): 279-285.

[49] Shruti Rao Kodi, M. Sunitha Reddy, Transferosomes: A Novel Topical Approach, Journal of Drug Delivery and Therapeutics, 2023, 13(2): 126-131.

[50] P. Kranthi Kumar and R. Santosh Kumar, Review on Transferosomes and Transferosomal gels, Journal of Pharmaceutical Research International, 2021, 33(43B): 114-126.

[51] Shakthi Apsara Thejani Opatha, Varin Titapiwatanakun and Romchat Chutoprapat, Transfersomes: A Promising Nanoencapsulation Technique for Transdermal Drug Delivery, Pharmaceutics 2020, 12, 855: 1-23.

[52] Jadupati *Malakar et al*, Formulation, optimization and evaluation of transferosomal gel for transdermal insulin delivery, Saudi Pharm J 2012 Oct;20(4):355-63. Doi: 10.1016/j.jsps.2012.02.001.

[53] Saeed Ghanbarzadeh *et al*. Enhances transdermal delivery of diclofenac sodium via conventional liposomes and transferosomes Biomed Res Int

2013:2013:616810. Doi: 10.1155/2013/616810.

[54] Shaik. Samifar, Shaik. Shaheda sultana, V. Vasu Naik, K. Madhuri, Ethosomes-an emerging approaches for vesicular delivery system, International Journal of Universal Pharmacy and Bio Sciences, 2013; 2(5): 356-73.

[55] Marwa H abdallah Formulation, development and evaluation of ibuprofen loaded nano transferosomal gel for the treatment of psoriasis. Journal of pharmaceutical research international 2019 31(6) DOI: 10.9734/jpri/2019/v31i630356

[56] Abdallah, M. H., Lila, A. S. A., Anwer, M. K., Khafagy, E.-S., Mohammad, M. and S. Soliman, M. (2019) "Formulation, Development and Evaluation of Ibuprofen Loaded Nano-transferosomal Gel for the Treatment of Psoriasis", *Journal of Pharmaceutical Research International*, 31(6), pp. 1–8. doi: 10.9734/jpri/2019/v31i630356.

[57] Lovely chaurasia Topical drug delivery of ketoconazole entrapped transferosomal gel with to design and enactment IJPSR.
DOI: 10.13040/IJPSR.0975-8232.12(12).6615-21

[58] Duangjit S, Characterization and in vitro skin permeation of meloxicam-loaded liposomes versus transfersomes. J.Drug Del.2010;1-9

[59] Trotta M, Deformable liposomes for dermal administration of methotrexate. Int. J. Pharm. 270.2004;119-25.

[60] Moawad, F.A.; Ali, A.A.; Salem, H.F. Nanotransfersomes-loaded thermosensitive in situ gel as a rectal Delivery system of tizanidine HCl: Preparation, in vitro and in vivo performance. Drug Deliv. 2017, 24, 252–260

[61] Chen RP, Chavda VP, Patel AB, Chen ZS. Phytochemical Delivery Through Transferosome (Phytosome): An Advanced Transdermal Drug Delivery for Complementary Medicines. Front Pharmacol. 2022 Feb 23;13:850862. doi: 10.3389/fphar.2022.850862. PMID: 35281927; PMCID: PMC8904565.

[62] Eleesha sana *et al* Topical delivery of cucurmin Loaded transferosomes gel Ameliorated Rheumatoid Arthritis by inhibiting NF_KB pathway nanomedicine 2021 Apr; 16(10): 819-837.
Doi: 10.2217/nnm-2020-0316.

[63] Rajan R, Jose S, Mukund VP, Vasudevan DT. Transferosomes - A vesicular transdermal delivery system for enhanced drug permeation. J Adv Pharm Technol Res. 2011 Jul; 2(3):138-43. doi: 10.4103/2231-4040.85524. PMID: 22171309; PMCID: PMC3217704.

[64] Alvi IA, Madan J, Kaushik D, Sardana S, Pandey RS, Ali A. Comparative study

of transfersomes, liposomes, and niosomes for topical delivery of 5-fluorouracil to skin cancer cells: preparation, characterization, in-vitro release, and cytotoxicity analysis. Anticancer Drugs. 2011 Sep;22(8):774-82. Doi: 10.1097/CAD.0b013e328346c7d6. P

[65] Dixena B, Madhariya R, Panday A, Ram A, Jain AK. Overcoming Skin Barrier with Transfersomes: Opportunities, Challenges, and Applications. Curr Drug Deliv. 2025;22(2):160-180. doi: 10.2174/0115672018272012231213100535. PMID: 38178667.

[66] Fernández-García R, Lalatsa A, Statts L, Bolás-Fernández F, Ballesteros MP, Serrano DR. Transferosomes as nanocarriers for drugs across the skin: Quality by design from lab to industrial scale. Int J Pharm. 2020 Jan 5;573:118817. Doi: 10.1016/j.ijpharm.2019.118817.

[67] Kaur P, Muskan, Kriplani P. Quality by design for Niosome-Based nanocarriers to improve transdermal drug delivery from lab to industry. Int J Pharm. 2024 Dec 5;666:124747. doi: 10.1016/j.ijpharm.2024.124747. Epub 2024 Sep 24. PMID: 39326474.

[68] Wu PS, Li YS, Kuo YC, Tsai SJ, Lin CC. Preparation and Evaluation of Novel Transfersomes Combined with the Natural Antioxidant Resveratrol. Molecules. 2019 Feb 8;24(3):600. Doi: 10.3390/molecules24030600.

[69] Rasul A, Imran Khan M, Ur Rehman M, Abbas G, Aslam N, Ahmad S, Abbas K, Akhtar Shah P, Iqbal M, Ahmed Al Subari AM, Shaheer T, Shah S. In vitro Characterization and Release Studies of Combined Nonionic Surfactant-Based Vesicles for the Prolonged Delivery of an Immunosuppressant Model Drug. Int J Nanomedicine. 2020 Oct 14;15:7937-7949. doi: 10.2147/IJN.S268846. PMID: 33116510; PMCID: PMC7569247.

[70] Badr-Eldin SM, Ahmed OA. Optimized nano-transfersomal films for enhanced sildenafil citrate transdermal delivery: ex vivo and in vivo evaluation. Drug Des Devel Ther. 2016 Apr 5;10:1323-33. Doi: 10.2147/DDDT.S103122.

[71] Shreya AB, Managuli RS, Menon J, Kondapalli L, Hegde AR, Avadhani K, Shetty PK, Amirthalingam M, Kalthur G, Mutalik S. Nano-transfersomal formulations for transdermal delivery of asenapine maleate: in vitro and in vivo performance evaluations. J Liposome Res. 2016 Sep;26(3):221-32. doi: 10.3109/08982104.2015.1098659. Epub 2015 Nov 30. PMID: 26621370.

[72] Kumar, M.S. Preeti Development of celecoxibtransfersomal gel for the treatment of rheumatoid arthritis.Indian

J. Pharm. Boil. Res. 2014, 2, 7–13 Doi: 10.30750/IJPBR.2.2.2

[73] El-Tokhy FS, Abdel-Mottaleb MMA, El-Ghany EA, Geneidi AS. Design of long acting invasomal nanovesicles for improved transdermal permeation and bioavailability of asenapine maleate for the chronic treatment of schizophrenia. Int J Pharm. 2021 Oct 25;608:121080. doi: 10.1016/j.ijpharm.2021.121080. Epub 2021 Sep 15. PMID: 34506923.

[74] Duangjit, S.; Opanasopit, P.; Rojanarata, T.; Ngawhirunpat, T. Characterization and in vitro skin permeation of meloxicam-loaded Liposomes versus Transfersomes. J. Drug Deliv. 2010, 2011, 1–9. Doi: 10.1155/2011/418316. Epub 2010 Nov 7.

[75] 75. Kamran M, Ahad A, Aqil M, Imam SS, Sultana Y, Ali A. Design, formulation and optimization of novel soft nano-carriers for transdermal olmesartanmedoxomil delivery: In vitro characterization and in vivo pharmacokinetic assessment. Int J Pharm. 2016 May 30;505(1-2):147-58. doi: 10.1016/j.ijpharm.2016.03.030. Epub 2016 Mar 19. PMID: 27005906.

[76] Parkash, V.; Maan, S.; Chaudhary, V.; Jogpal, V.; Mittal, G.; Jain, V. Implementation of design of experiments in development and optimization of transfersomal carrier system of tacrolimus for the dermal management of psoriasis in albino wistar rat. J. Bioequiv. Availab. 2018, 10, 98–105. Doi:10.4172/0975-0851.1000385

[77] Akhtar N, Varma A, Pathak K. Ethosomes as Vesicles for Effective Transdermal Delivery: From Bench to Clinical Implementation. Curr Clin Pharmacol. 2016;11(3):168-190. doi: 10.2174/1574884711666160813231352 . PMID: 27526697.

[78] Sarwa, K.K.; Mazumder, B.; Rudrapal, M.; Verma, V.K. Potential of capsaicin-loaded transfersomes in arthritic Rats. Drug Deliv. 2014, 22, 638–646. Doi: 10.3109/10717544.2013.871601.

[79] Khan NR, Harun MS, Nawaz A, Harjoh N, Wong TW. Nanocarriers and their Actions to Improve Skin Permeability and Transdermal Drug Delivery. Curr Pharm Des. 2015; 21(20): 2848-66. doi: 10.2174/1381612821666150428145216 . PMID: 25925113.

[80] Bhatia, A.; Usha, K.; Wadhwa, S.; Raza, K.; Katare, O.P. Novel phospholipid-based topical formulations Of tamoxifen: Evaluation for antipsoriatic activity using mouse-tail model. Pharm. Dev. Technol. 2013, 19,160–163. Doi: 10.3109/10837450.2013.763260

[81] Wong TW. Electrical, magnetic, photomechanical and cavitational waves to overcome skin barrier for transdermal drug delivery. J Control Release. 2014

Nov 10;193:257-69. doi: 10.1016/j.jconrel.2014.04.045. Epub 2014 May 5. PMID: 24801250.

[82] Amin, S.; Sarfenejad, A.; Ahmad, J.; Kohli, K.; Mir, S.R. Nanovesiculartransfersomes for enhanced systemic delivery of telmisartan. Adv. Sci. Eng. Med. 2013, 5, 299–308 Doi: 10.3390/pharmaceutics12090855

[83] Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci. 2001 Sep;14(2):101-14. doi: 10.1016/s0928-0987(01)00167-1. PMID: 11500256.

[84] Mahmood, S.; Chatterjee, B.; Mandal, U.K. Nano transfersomes vesicles of raloxifene hcl with sorbitan 80: Formulation and characterization. Bioequivalence Bioavailab. Int. J. 2018, 2, 1–7 DOI:10.23880/BEBA-16000121

[85] Brown MB, Martin GP, Jones SA, Akomeah FK. Dermal and transdermal drug delivery systems: current and future prospects. Drug Deliv. 2006 May-Jun;13(3):175-87. doi: 10.1080/10717540500455975. PMID: 16556569.

[86] Ascenso, A., Salgado, A., Euleterio, C., Praca, F.G., Bentley, M.V., Marques, H.C., Oliveira, H., Santos, C., Simoes, S., 2014. In vitro and in vivo topical delivery studies of tretinoinloadedultradeformable vesicles. Eur J Pharm Biopharm 88, 48-55. Doi: 10.1016/j.ejpb.2014.05.002.

[87] Raphael AP, Wright OR, Benson HA, Prow TW. Recent advances in physical delivery enhancement of topical drugs. Curr Pharm Des. 2015;21(20):2830-47. doi: 10.2174/1381612821666150428144852. PMID: 25925114.

[88] Design Expert software. Stat-Ease, https://shop.statease.com/software/design-expert/. Abdellatif, A.A., Tawfeek, H.M., 2016. Transfersomal Nanoparticles for Enhanced Transdermal Delivery of Clindamycin. AAPS PharmSciTech 17, 1067-1074 Doi: 10.1208/s12249-015-0441-7.

[89] Zhu C, Wang XY, Zhao J, Long B, Xiao X, Pan LY, Yuan TF, Chen JH. Effect of transdermal drug delivery therapy on anxiety symptoms in schizophrenic patients. Front Neurosci. 2023 Jun 9;17:1177214. doi: 10.3389/fnins.2023.1177214. PMID: 37360162; PMCID: PMC10289061.

[90] 90. Wang, J., Wei, Y., Fei, Y.R., Fang, L., Zheng, H.S., Mu, C.F., Li, F.Z., Zhang, Y.S., 2017. Preparation of mixed monoterpenes edge activated PEGylated transfersomes to improve the in vivo transdermal delivery efficiency of sinomenine hydrochloride. Int J Pharm

533, 266-274. Doi: 10.1016/j.ijpharm.2017.09.059.

[91] Natsheh H, Touitou E. Phospholipid Vesicles for Dermal/Transdermal and Nasal Administration of Active Molecules: The Effect of Surfactants and Alcohols on the Fluidity of Their Lipid Bilayers and Penetration Enhancement Properties. Molecules. 2020 Jun 27;25(13):2959. doi: 10.3390/molecules25132959. PMID: 32605117; PMCID: PMC7412180.

[92] Abdallah MH, Shahien MM, El-Horany HE, Ahmed EH. Modified Phospholipid Vesicular Gel for Transdermal Drug Delivery: The Influence of Glycerin and/or Ethanol on Their Lipid Bilayer Fluidity and Penetration Characteristics. Gels. 2025 May 13;11(5):358. doi: 10.3390/gels11050358. PMID: 40422378; PMCID: PMC12110836.

[93] Touitou E, Natsheh H. Topical Administration of Drugs Incorporated in Carriers Containing Phospholipid Soft Vesicles for the Treatment of Skin Medical Conditions. Pharmaceutics. 2021 Dec 10;13(12):2129. doi: 10.3390/pharmaceutics13122129. PMID: 34959410; PMCID: PMC8706871.

[94] Natsheh H, Vettorato E, Touitou E. Ethosomes for Dermal Administration of Natural Active Molecules.CurrPharmDes.2019;25(21): 2338-2348. doi: 10.2174/1381612825666190716095826. PMID: 31333087.

[95] Abu-Huwaij R, Zidan AN. Unlocking the potential of cosmetic dermal delivery with ethosomes: A comprehensive review. J Cosmet Dermatol. 2024 Jan;23(1):17-26. doi: 10.1111/jocd.15895. Epub 2023 Jul 2. PMID: 37393573.

[96] Paiva-Santos AC, Silva AL, Guerra C, Peixoto D, Pereira-Silva M, Zeinali M, Mascarenhas-Melo F, Castro R, Veiga F. Ethosomes as Nanocarriers for the Development of Skin Delivery Formulations. Pharm Res. 2021 Jun;38(6):947-970. doi: 10.1007/s11095-021-03053-5. Epub 2021 May 25. PMID: 34036520.

[97] Yang L, Wu L, Wu D, Shi D, Wang T, Zhu X. Mechanism of transdermal permeation promotion of lipophilic drugs by ethosomes. Int J Nanomedicine. 2017 Apr 26;12:3357-3364. doi: 10.2147/IJN.S134708. PMID: 28490875; PMCID: PMC5413537.

[98] Zhu X, Li F, Peng X, Zeng K. Formulation and evaluation of lidocaine base ethosomes for transdermal delivery. Anesth Analg. 2013 Aug;117(2):352-7. doi: 10.1213/ANE.0b013e3182937b74. Epub 2013 Jun 6. PMID: 23744957.

[99] Sapkota R, Dash AK. Liposomes and transferosomes: a breakthrough in topical and transdermal delivery. Ther Deliv. 2021 Feb;12(2):145-158. doi: 10.4155/tde-2020-0122. Epub 2021 Feb 15. PMID: 33583219.

[100] Chacko IA, Ghate VM, Dsouza L, Lewis SA. Lipid vesicles: A versatile drug delivery platform for dermal and transdermal applications. Colloids Surf B Biointerfaces. 2020 Nov;195:111262. doi: 10.1016/j.colsurfb.2020.111262. Epub 2020 Jul 17. PMID: 32736123.